Loading
companiesCompany
Xynomic Pharmaceuticals
Xynomic Pharmaceuticals is a Chinese-American biotech that licensed the histone deacetylase inhibitor abexinostat from Pharmacyclics and is testing it with pazopanib in kidney cancer and alone in lymphoma.
Also called: Xynomic Pharmaceuticals HoldingsXynomic Pharma
Overview
Xynomic Pharmaceuticals is an oncology company with operations in Zhongshan, Guangdong and the San Francisco Bay Area. Its lead asset is abexinostat, a pan-histone deacetylase inhibitor in-licensed from Pharmacyclics (now part of AbbVie), which it has taken into a phase 3 trial with pazopanib in renal cell carcinoma and into follicular lymphoma studies in China. It also holds rights to the pan-RAF inhibitor XP-102 and other clinical-stage assets.
Headquarters
Zhongshan, CN
Scorecard
All companies#385of 1244 companies, score 10
- phase 3 +3
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 0 targets, 7 registry studies. Formula on the scorecards page.
Type
Website
Phase 3small molecule
Abexinostat is an experimental small-molecule drug from Xynomic Pharmaceuticals in phase 3 trials for renal cell carcinoma, diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.
drugs
Phase 3small molecule
trials
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese PatientsA Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaA Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Study of Abexinostat in Patients With Relapsed or Refractory Follicular LymphomaStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation